Trial Profile
Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 04 Jan 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, according to ClinicalTrials.gov record.
- 03 Sep 2013 New trial record